Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 36.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,667 shares of the company’s stock after purchasing an additional 14,134 shares during the quarter. Y Intercept Hong Kong Ltd owned approximately 0.06% of Myriad Genetics worth $722,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of MYGN. Point72 Hong Kong Ltd acquired a new stake in shares of Myriad Genetics in the third quarter valued at about $32,000. KBC Group NV grew its position in shares of Myriad Genetics by 132.8% in the fourth quarter. KBC Group NV now owns 5,845 shares of the company’s stock valued at $80,000 after purchasing an additional 3,334 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Myriad Genetics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock valued at $87,000 after purchasing an additional 583 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its position in shares of Myriad Genetics by 43.8% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock valued at $132,000 after purchasing an additional 1,471 shares during the period. Finally, Meeder Asset Management Inc. grew its position in shares of Myriad Genetics by 588.4% in the third quarter. Meeder Asset Management Inc. now owns 4,922 shares of the company’s stock valued at $135,000 after purchasing an additional 4,207 shares during the period. Institutional investors and hedge funds own 99.02% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Stephens reiterated an “equal weight” rating and issued a $20.00 target price on shares of Myriad Genetics in a research report on Thursday, January 16th. Craig Hallum started coverage on shares of Myriad Genetics in a research note on Wednesday, February 12th. They issued a “buy” rating and a $29.00 price target on the stock. StockNews.com downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Saturday. Leerink Partnrs downgraded shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Finally, UBS Group decreased their price target on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $22.14.

Myriad Genetics Price Performance

Shares of MYGN stock opened at $10.73 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The firm’s 50-day moving average is $13.28 and its two-hundred day moving average is $19.04. Myriad Genetics, Inc. has a 12 month low of $9.76 and a 12 month high of $29.30. The company has a market capitalization of $976.81 million, a PE ratio of -8.25 and a beta of 1.88.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). The company had revenue of $210.60 million during the quarter, compared to analysts’ expectations of $210.35 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same period last year, the firm posted ($0.12) earnings per share. Analysts predict that Myriad Genetics, Inc. will post -0.3 earnings per share for the current year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.